D S Small

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis
    William L Macias
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Ind 46285, USA
    Clin Pharmacol Ther 72:391-402. 2002
  2. doi request reprint The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Thromb Haemost 99:409-15. 2008
  3. doi request reprint Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center DC 0724, Indianapolis, IN 46285, USA
    J Clin Pharmacol 48:475-84. 2008
  4. doi request reprint Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 24:2251-7. 2008
  5. doi request reprint Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Drugs Aging 26:781-90. 2009
  6. doi request reprint Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease
    D S Small
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Pharm Ther 34:575-83. 2009
  7. doi request reprint Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease
    D S Small
    Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Pharm Ther 34:585-94. 2009
  8. doi request reprint The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur J Clin Pharmacol 66:127-35. 2010
  9. doi request reprint Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Clin Ther 32:365-79. 2010
  10. doi request reprint Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Pharmacol 51:321-32. 2011

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis
    William L Macias
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Ind 46285, USA
    Clin Pharmacol Ther 72:391-402. 2002
    ..We aimed to characterize the pharmacokinetics and pharmacodynamics of drotrecogin alfa (activated) (recombinant human activated protein C) in patients with severe sepsis...
  2. doi request reprint The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Thromb Haemost 99:409-15. 2008
    ..The determination of the clinical utility of such POC devices will require their use in clinical outcome studies...
  3. doi request reprint Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center DC 0724, Indianapolis, IN 46285, USA
    J Clin Pharmacol 48:475-84. 2008
    ..The overall data suggest that a prasugrel dose adjustment is not likely warranted in an individual taking prasugrel with a proton pump inhibitor such as lansoprazole...
  4. doi request reprint Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 24:2251-7. 2008
    ..This study evaluated the influence of ranitidine coadministration on the pharmacokinetics and pharmacodynamics of the respective active metabolite of prasugrel and clopidogrel...
  5. doi request reprint Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Drugs Aging 26:781-90. 2009
    ..Prasugrel is a novel antiplatelet agent approved for the treatment of ACS patients undergoing percutaneous coronary intervention, and will be used in this population...
  6. doi request reprint Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease
    D S Small
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Pharm Ther 34:575-83. 2009
    ..As hepatic enzymes play a key role in formation of prasugrel's active metabolite, hepatic impairment could affect the safety and/or efficacy of prasugrel in such patients...
  7. doi request reprint Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease
    D S Small
    Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Pharm Ther 34:585-94. 2009
    ..The pharmacokinetic (PK) and pharmacodynamic (PD) responses to prasugrel were compared in three studies of healthy subjects vs. those with moderate or end-stage renal impairment...
  8. doi request reprint The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur J Clin Pharmacol 66:127-35. 2010
    ..We compared prasugrel pharmacokinetics, pharmacodynamics, and tolerability in healthy Chinese, Japanese, Korean and Caucasian subjects...
  9. doi request reprint Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Clin Ther 32:365-79. 2010
    ..Although the approved loading dose is 60 mg, earlier studies of prasugrel suggested that active-metabolite exposure and pharmacodynamic response may be higher in Asian subjects than in white subjects...
  10. doi request reprint Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Pharmacol 51:321-32. 2011
    ..These results characterize prasugrel's PK across a range of studies and highlight body weight as the most influential covariate on prasugrel AM exposure, with implications for prasugrel maintenance dosing in clinical practice...
  11. doi request reprint Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Pharmacokinet 49:777-98. 2010
    ..Although prasugrel did not alter warfarin pharmacokinetics, prasugrel and warfarin should not be used together, because of an increased bleeding risk associated with their concomitant use...
  12. ncbi request reprint Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
    N A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Clin Pharmacol Ther 81:735-41. 2007
    ..We conclude that CYP3A4 and CYP3A5 inhibition by ketoconazole affects formation of clopidogrel's but not prasugrel's active metabolite. The decreased formation of clopidogrel's active metabolite is associated with reduced IPA...
  13. doi request reprint Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects
    N A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 6285, USA
    Curr Med Res Opin 25:1821-9. 2009
    ....
  14. doi request reprint Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation
    M U Zafar
    Mount Sinai School of Medicine, New York, NY Eli Lilly and Company, Indianapolis, IN, USA
    J Thromb Haemost 11:100-6. 2013
    ..Hemostatic benefits of platelet transfusions in thienopyridine-treated acute coronary syndrome (ACS) patients may be compromised by residual metabolite in circulation...
  15. ncbi request reprint Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
    Christopher D Payne
    Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
    J Cardiovasc Pharmacol 50:555-62. 2007
    ..In conclusion, greater exposure to prasugrel's active metabolite results in faster onset, higher levels, and less variability of platelet inhibition compared with high-dose clopidogrel in healthy subjects...
  16. doi request reprint Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects
    Christopher D Payne
    Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK
    Platelets 19:275-81. 2008
    ..Switching directly from clopidogrel MD to either prasugrel LD or MD was well tolerated and resulted in significantly greater levels of platelet inhibition than a clopidogrel 75 mg MD...
  17. doi request reprint A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Cardiovasc Pharmacol 56:29-37. 2010
    ..This integrated analysis supports the findings of earlier individual studies comparing these methodologies that assess platelet function...
  18. ncbi request reprint The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Cardiovasc Pharmacol 47:377-84. 2006
    ..Prasugrel LDs and MDs provide rapid and sustained inhibition of ADP-mediated platelet aggregation...
  19. ncbi request reprint A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
    John T Brandt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am Heart J 153:66.e9-16. 2007
    ..Thienopyridines are prodrugs, metabolized in vivo to active metabolites that inhibit the platelet P2Y12 adenosine diphosphate (ADP) receptor...
  20. pmc Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects
    Clark Chan
    Lilly NUS Centre for Clinical Pharmacology, National University of Singapore, Singapore
    Br J Clin Pharmacol 63:310-4. 2007
    ..To compare single- and multiple-dose duloxetine pharmacokinetics between healthy Japanese and Caucasians...
  21. doi request reprint Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects
    Ying G Li
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Platelets 20:316-27. 2009
    ..Gender, race, body weight, and age were identified as statistically significant covariates impacting platelet inhibition...
  22. doi request reprint Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38
    Rebecca E Wrishko
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Pharmacol 49:984-98. 2009
    ..1%) was 30% (90% confidence interval [CI] 1.16-1.45) higher than exposure in patients > or =60 kg. Mean Pras-AM exposures for patients > or =75 years (10.5%) were 19% (90% CI: 1.11-1.28) higher compared with patients <75 years...
  23. ncbi request reprint Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
    Nagy A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Pharmacol 48:53-9. 2008
    ..These results are consistent with patients receiving prasugrel not requiring dose adjustments when treated with drugs primarily metabolized by CYP2B6...
  24. doi request reprint Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects
    Nagy A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Pharmacotherapy 28:1483-94. 2008
    ..To investigate the potential effect of atorvastatin 80 mg/day on the pharmacokinetics and pharmacodynamics of the thienopyridines prasugrel and clopidogrel...
  25. doi request reprint Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease
    C Steven Ernest
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharmacokinet Pharmacodyn 35:593-618. 2008
    ..The greater PD response with prasugrel compared with clopidogrel was accounted for by greater conversion of dose to active metabolite...
  26. doi request reprint A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Thromb Haemost 99:215-22. 2008
    ..86, p < 0.0001). VASP and LTA demonstrated concordance across the response range of P2Y(12) receptor blockade following thienopyridine LDs...
  27. ncbi request reprint Comment: obese man treated with drotrecogin alfa (activated)
    David S Small
    Ann Pharmacother 38:722-3; author reply 723. 2004
  28. ncbi request reprint Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis
    Phil Barton
    Department of Pediatrics, Division of Pediatric Critical Care, Children s Hospital at Saint Francis, Tulsa, Oklahoma, USA
    Pediatrics 113:7-17. 2004
    ..We have now performed a preliminary analysis of the safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in pediatric patients with severe sepsis...
  29. ncbi request reprint Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease
    David S Small
    Allergan, Inc Irvine, CA 92715, USA
    J Ocul Pharmacol Ther 18:411-8. 2002
    ..1% CsA-treated patient. These results indicate that long-term use of topical CsA ophthalmic emulsions at doses that are clinically efficacious for treating dry eye will not cause any system-wide effects...